Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer.
Date AA, Kates M, Yoshida T, Babu T, Afzal U, Kanvinde P, Baras A, Anders N, He P, Rudek M, Hanes J, Bivalacqua TJ, Ensign LM. Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer. Drug Deliv Transl Res. 2021 10; 11(5):2085-2095.